Immix Biopharma, Inc. (IMMX)
NASDAQ: IMMX · IEX Real-Time Price · USD
2.090
+0.010 (0.48%)
Jul 22, 2024, 10:06 AM EDT - Market open
Immix Biopharma Employees
As of December 31, 2023, Immix Biopharma had 17 total employees, including 14 full-time and 3 part-time employees. The number of employees increased by 6 or 54.55% compared to the previous year.
Employees
17
Change (1Y)
6
Growth (1Y)
54.55%
Revenue / Employee
n/a
Profits / Employee
-$1,070,904
Market Cap
55.73M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 17 | 6 | 54.55% |
Dec 31, 2022 | 11 | 9 | 450.00% |
Dec 31, 2021 | 2 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Allurion Technologies | 504 |
Atara Biotherapeutics | 225 |
Barinthus Biotherapeutics | 130 |
Turnstone Biologics | 80 |
CollPlant Biotechnologies | 75 |
Passage Bio | 58 |
Rallybio | 43 |
LAVA Therapeutics | 37 |
IMMX News
- 14 days ago - Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201 - GlobeNewsWire
- 5 weeks ago - Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum - GlobeNewsWire
- 2 months ago - Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation - GlobeNewsWire
- 3 months ago - Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma - GlobeNewsWire
- 3 months ago - Immix Biopharma on Track to Dose NXC-201 Patients in United States - GlobeNewsWire
- 3 months ago - Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) - GlobeNewsWire
- 4 months ago - Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial - GlobeNewsWire
- 4 months ago - Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative - GlobeNewsWire